Xeris Biopharma Holdings (XERS) Amortization - Intangibles (2021 - 2026)
Xeris Biopharma Holdings' (XERS) quarterly Amortization - Intangibles came in at $2.7 million in Q1 2026, little changed YoY from $2.7 million in Q1 2025, and little changed on a QoQ basis from $2.7 million in Q4 2025.
Xeris Biopharma Holdings (XERS) Amortization - Intangibles (2021 - 2026) Analysis & Trends
Xeris Biopharma Holdings (XERS) has 6 years of Amortization - Intangibles data on file, last reported at $2.7 million in Q1 2026.
- Quarterly Amortization - Intangibles changed 0.0% year-over-year to $2.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.8 million (changed 0.01% YoY) and the FY2025 annual result came in at $10.8 million, changed 0.0% from the prior year.
- Amortization - Intangibles held at $2.7 million in Q1 2026, from $2.7 million in the prior quarter.
- In the past five years, Amortization - Intangibles ranged from a high of $2.7 million in Q1 2022 to a low of $2.7 million in Q2 2022.
- A 5-year average of $2.7 million and a median of $2.7 million in 2022 frame the typical range for Amortization - Intangibles.
- Annual changes were most pronounced in 2022 — Amortization - Intangibles jumped 392.91% — and 2025, when it slipped 0.04%.
- Tracing XERS's Amortization - Intangibles over 5 years: stood at $2.7 million in 2022, then changed by 0.0% to $2.7 million in 2023, then changed by 0.0% to $2.7 million in 2024, then changed by 0.0% to $2.7 million in 2025, then decreased by 0.04% to $2.7 million in 2026.
- The last three Amortization - Intangibles figures came in at $2.7 million (Q1 2026), $2.7 million (Q4 2025), and $2.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.41 Bn | 39.75 Bn | 2.15 Bn |
| 3 | Zoetis | 31.83 Bn | 30.15 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.97 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.93 Bn | 11.40 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - |
| 10 | Xeris Biopharma Holdings | 1.50 Bn | 1.37 Bn | 79.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.71 Mn |
| Mar 31, 2026 | 2.71 Mn |
| Dec 31, 2025 | 2.71 Mn |
| Sep 30, 2025 | 2.71 Mn |
| Jun 30, 2025 | 2.71 Mn |
| Mar 31, 2025 | 2.71 Mn |
| Dec 31, 2024 | 2.71 Mn |
| Sep 30, 2024 | 2.71 Mn |
| Jun 30, 2024 | 2.71 Mn |
| Mar 31, 2024 | 2.71 Mn |
| Dec 31, 2023 | 2.71 Mn |
| Sep 30, 2023 | 2.71 Mn |
| Jun 30, 2023 | 2.71 Mn |
| Mar 31, 2023 | 2.71 Mn |
| Dec 31, 2022 | 2.71 Mn |
| Sep 30, 2022 | 2.71 Mn |
| Jun 30, 2022 | 2.71 Mn |
| Mar 31, 2022 | 2.71 Mn |
| Dec 31, 2021 | 550,000.00 |